2024-03-29T12:25:24Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1994922020-02-04T02:33:15Zcom_10261_54com_10261_1col_10261_307
00925njm 22002777a 4500
dc
Galán-Arriero, Iriana
author
Avila-Martín, Gerardo
author
Ferrer-Donato, Águeda
author
Gómez-Soriano, Julio
author
Piazza, Stefano
author
Taylor, Julian S.
author
2015
Microglia cell activation plays a role in the development of neuropathic pain partly due to the activation of the p38α MAPK signaling pathway after nerve injury. In this study we assessed the effect of UR13870, a p38α MAPK inhibitor, in the “spared nerve injury” (SNI) model, to study its effects on modulation of spinal microglial activation and to test behavioral hyperreflexia responses and cerebral-mediated pain behavior. The effect of daily administration of UR13870 (10 mg/kg p.o.) and Pregabalin (50 mg/kg p.o.) on reflex hypersensitivity to mechanical and cold test stimuli and on affective related pain responses measured with the place escape avoidance paradigm and the open field-induced anxiety test, were evaluated after SNI in Sprague Dawley rats. Microglial reactivity in the ipsilateral lumbar laminae I/II dorsal horn was evaluated with OX-42 immunohistochemistry. UR13870 treatment significantly decreased hindlimb hyperreflexia to both mechanical and cold stimuli after SNI without loss of general motor function, in addition to a reduction in pain-related anxiety behavior at day 21 after SNI, accompanied by normalization of OX-42 immunoreactivity within the ipsilateral lumbar dorsal horn. Pregabalin treatment only reduced mechanical hyperreflexia and affected general motor function. Oral administration of the p38α MAPK inhibitor, UR13870, mediates antinociception to both mechanical and cold stimuli, and significantly restored inner-zone exploration in the open field test, accompanied by normalization in dorsal horn microglial activation in the SNI model.
Neuroscience Letters 604: 69-74 (2015)
0304-3940
http://hdl.handle.net/10261/199492
10.1016/j.neulet.2015.07.044
1872-7972
http://dx.doi.org/10.13039/501100004837
http://dx.doi.org/10.13039/100008061
http://dx.doi.org/10.13039/501100004587
Spared nerve injury
Neuropathic pain
p38α MAPK inhibitor
Antinociception
Microglia
OX-42
Place escape/avoidance paradigm
Open field induced anxiety test
Early treatment with UR13870, a novel inhibitor of p38α mitogenous activated protein kinase, prevents hyperreflexia and anxiety behaviors, in the spared nerve injury model of neuropathic pain